propidium has been researched along with HIV Infections in 6 studies
Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.
HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Massanella, M | 1 |
| Curriu, M | 1 |
| Carrillo, J | 1 |
| Gómez, E | 1 |
| Puig, J | 1 |
| Navarro, J | 1 |
| Dalmau, J | 1 |
| Martínez-Picado, J | 1 |
| Crespo, M | 1 |
| Cabrera, C | 1 |
| Negredo, E | 1 |
| Clotet, B | 1 |
| Blanco, J | 1 |
| Pitrak, DL | 1 |
| Novak, RM | 1 |
| Estes, R | 1 |
| Tschampa, J | 1 |
| Abaya, CD | 1 |
| Martinson, J | 1 |
| Bradley, K | 1 |
| Tenorio, AR | 1 |
| Landay, AL | 1 |
| Palma, PF | 1 |
| Baggio, GL | 1 |
| Spada, C | 1 |
| Silva, RD | 1 |
| Ferreira, SI | 1 |
| Treitinger, A | 1 |
| Panagio, LA | 1 |
| Felipe, I | 1 |
| Vidotto, MC | 1 |
| Gaziri, LCJ | 1 |
| Godoy-Ramirez, K | 1 |
| Mäkitalo, B | 1 |
| Thorstensson, R | 1 |
| Sandström, E | 1 |
| Biberfeld, G | 1 |
| Gaines, H | 1 |
| Dieye, TN | 1 |
| Van Vooren, JP | 1 |
| Delforge, ML | 1 |
| Liesnard, C | 1 |
| Devleeschouwer, M | 1 |
| Farber, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based Versus an Efavirenz-based HAART (Highly Active Antiretroviral Therapy) Regimen in Antiretroviral-Naïve Subjects With Advanced HIV Disease[NCT00775606] | Phase 4 | 15 participants (Actual) | Interventional | 2008-10-31 | Terminated (stopped due to Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in the percentage of naive CD4 T-cells undergoing apoptosis as measured by propidium iodide staining. This is a lab test that measures the percentage of naive CD4 T-cells that are undergoing cell death. The change in this measure is obtained by determining the difference between the percentage of naive CD4 T-cells undergoing apoptosis at week 24 of treatment and the percentage undergoing apoptosis at baseline. (NCT00775606)
Timeframe: 24 weeks from treatment initiation (baseline and week 24)
| Intervention | per cent (Mean) |
|---|---|
| ARM A/Lopinavir-ritonavir | -12.33 |
| ARM B/Efavirenz | -8.01 |
This measures the change in CD4+ T-cells from baseline to week 24 of treatment. (NCT00775606)
Timeframe: 24 weeks after treatment initiation (baseline and week 24)
| Intervention | cells/mm3 (Mean) |
|---|---|
| ARM A/Lopinavir-ritonavir | 176.83 |
| ARM B/Efavirenz | 102.6 |
Activation of CD4+ and CD8+ T cells were measured at week 24 (NCT00775606)
Timeframe: week 24 measurements
| Intervention | percentage of cells (Mean) | |||
|---|---|---|---|---|
| Activation of CD4+ T cells at week 24 | Activation of CD8+ T cells at week 24 | Proliferation of CD4+ T cells at week 24 | Proliferation of CD8+ T cells at week 24 | |
| ARM A Lopinavir-ritonavir | 8.70 | 20.92 | 0.47 | 0.81 |
| ARM B Efavirenz | 7.39 | 17.17 | 0.52 | 0.48 |
Activation and proliferation of CD4+ and CD8+ T cells were measured at baseline (NCT00775606)
Timeframe: baseline measurements
| Intervention | percentage of cells (Mean) | |||
|---|---|---|---|---|
| Activation of CD4+ T cells at baseline | Activation of CD8+ T cells at baseline | Proliferation of CD4+ T cells at baseline | Proliferation of CD8+ T cells at baseline | |
| ARM A Lopinavir-ritonavir | 12.85 | 34.61 | 1.21 | 1.39 |
| ARM B Efavirenz | 12.35 | 33.57 | 1.25 | 1.25 |
Naive, central memory and effector memory, and T reg CD4+ T-cell frequency at week 24 (NCT00775606)
Timeframe: week 24 measurements
| Intervention | percentage of cells (Mean) | |||
|---|---|---|---|---|
| Mean percentage of naive CD4+ T cells at week 24 | Mean percentage of central memory CD4+ T cells at week 24 | Mean percentage of effector memory CD4+ T cells at week 24 | Mean percentage of CD4+ Treg cells at week 24 | |
| ARM A Lopinavir/Ritonavir | 29.08 | 10.89 | 34.98 | 5.58 |
| ARM B Efavirenz | 25.73 | 8.28 | 44.82 | 5.51 |
Naive, central memory, effector memory, and T reg CD4+ T-cell frequency at baseline (NCT00775606)
Timeframe: baseline measurements
| Intervention | percentage of cells (Mean) | |||
|---|---|---|---|---|
| Mean percentage of naive CD4+ T cells at baseline | Mean percentage of central memory CD4+ T cells at baseline | Mean percentage of effector memory CD4+ T cells at baseline | Mean percentage of CD4+ Treg cells at baseline | |
| ARM A Lopinavir/Ritonavir | 32.67 | 11.54 | 36.44 | 7.35 |
| ARM B Efavirenz | 24.70 | 9.02 | 47.32 | 6.96 |
2 trials available for propidium and HIV Infections
| Article | Year |
|---|---|
Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Apoptosis; Caspases; CD4 Lymphocyte C | 2015 |
Spontaneous apoptosis and highly active antiretroviral therapy (HAART).
Topics: Adult; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cu | 2000 |
4 other studies available for propidium and HIV Infections
| Article | Year |
|---|---|
Assessing main death pathways in T lymphocytes from HIV infected individuals.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Benzimidazoles; Carbocyanines; Case-Control Studies; Cas | 2013 |
Evaluation of annexin V and Calcein-AM as markers of mononuclear cell apoptosis during human immunodeficiency virus infection.
Topics: Annexin A5; Apoptosis; Biomarkers; Cell Membrane Permeability; Ethidium; Flow Cytometry; Fluorescein | 2008 |
Early membrane exposure of phosphatidylserine followed by late necrosis in murine macrophages induced by Candida albicans from an HIV-infected individual.
Topics: AIDS-Related Opportunistic Infections; Animals; Annexin A5; Apoptosis; Candida albicans; Candidiasis | 2002 |
A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry.
Topics: Cells, Cultured; Chromium; Cytotoxicity, Immunologic; Flow Cytometry; Fluoresceins; HIV Antigens; HI | 2005 |